Esketamine Clinical Trial
Official title:
Chief Physician of the Department of Anesthesiology of the Southern Theater General Hospital
The propofol-refentanil program-controlled closed-loop target-controlled infusion system based on NI guidance has been clinically verified. In the case of clinical use of esketamine, the separation anesthesia properties do not affect the accuracy and safety of closed-loop system guidance. However, whether the specific degree of impact can be quantified, and based on quantitative indicators, this model can be better applied to a wider range of clinical actual conditions and different drug administration backgrounds.
The first phase is data collection on the effect of subanesthetic doses of esketamine on NI EEG in closed-loop target-controlled infusion systems for general anesthesia. According to the observation of pre-experiments and the latest literature at home and abroad, foreign studies have confirmed that esketamine does not affect the overall stability of the closed-loop system, and we verified the reliability of this conclusion through pre-experiments. In order to clarify the degree of influence of subanesthetic dose of esketamine on EEG, it is necessary to include a certain amount of esketamine applied to the anesthesia sample of closed-loop target controlled infusion system, through the main observation indicators: the change of EEG NI value after the administration of subanesthetic dose of esketamine during the anesthesia maintenance period, the change of EEG power spectrum, and the quantitative ratio change trend of brain waves (α, β, θ, δ waves). The difference in EEG NI value, power spectrum and dynamic transformation of brain wave increased due to the action of subanesthetic dose of esketamine was obtained, and the difference was quantified by the attribution of data to the degree of change of the actual EEG NI value. According to the preset guidance EEG NI value of the original closed-loop target-controlled infusion drug delivery system 36, the guidance preset value of the closed-loop system of 36+N in the clinical administration scenario of subanesthetic dose of esketamine was reset as the new EEG closed-loop feedback baseline. The second phase is the validation of the effect of esketamine equivalent to the subanesthetic dose on closed-loop target-controlled infusion general anesthesia based on regulated NI(36+N) feedback. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05506787 -
The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease
|
Phase 4 | |
Not yet recruiting |
NCT06062550 -
Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery
|
Phase 4 | |
Recruiting |
NCT06003218 -
Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
|
N/A | |
Recruiting |
NCT04664530 -
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
|
Phase 4 | |
Not yet recruiting |
NCT06117917 -
Esketamine Combined With Pregabalin on CPSP in Spinal Patients.
|
Phase 2/Phase 3 | |
Recruiting |
NCT05718024 -
Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality With Mechanical Ventilation
|
Phase 4 | |
Recruiting |
NCT05950646 -
Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality
|
Phase 4 | |
Recruiting |
NCT05732064 -
Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality
|
Phase 4 | |
Not yet recruiting |
NCT06389344 -
Effect of Esketamine on Conscious State in Patients With pDoC
|
N/A | |
Recruiting |
NCT04860661 -
Esketamine on Postpartum Depression in Cesarean Section Women
|
N/A | |
Completed |
NCT06398834 -
Esketamine and Butorphanol for Post-Lobectomy Pain
|
Phase 4 | |
Recruiting |
NCT06399185 -
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
|
Phase 4 | |
Recruiting |
NCT06451627 -
Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery
|
N/A | |
Completed |
NCT05458453 -
An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery
|
Phase 4 | |
Recruiting |
NCT04843982 -
Immunoinflammatory Regulation of Esketamine in Septic Patients
|
Phase 4 | |
Not yet recruiting |
NCT06468436 -
Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
|
N/A | |
Active, not recruiting |
NCT05718544 -
Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes
|
Phase 4 | |
Not yet recruiting |
NCT06087510 -
Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes
|
Phase 4 | |
Recruiting |
NCT06051227 -
Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial
|
Phase 3 | |
Recruiting |
NCT04425473 -
Esketamine and Perioperative Depressive Symptoms
|
Phase 2/Phase 3 |